Display options
Cite
Bradoo RA, Nerurkar NK, Mhapankar JB, et al. Management of acute vertigo with betahistine. Indian J Otolaryngol Head Neck Surg. 2000;52(2):151-8doi: 10.1007/BF03000335.
Bradoo, R. A., Nerurkar, N. K., Mhapankar, J. B., Patil, S. F., & Kute, D. G. (2000). Management of acute vertigo with betahistine. Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India, 52(2), 151-8. https://doi.org/10.1007/BF03000335
Bradoo, R A, et al. "Management of acute vertigo with betahistine." Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India vol. 52,2 (2000): 151-8. doi: https://doi.org/10.1007/BF03000335
Bradoo RA, Nerurkar NK, Mhapankar JB, Patil SF, Kute DG. Management of acute vertigo with betahistine. Indian J Otolaryngol Head Neck Surg. 2000 Apr;52(2):151-8. doi: 10.1007/BF03000335. PMID: 23119656; PMCID: PMC3451274.
Copy Download .nbib Format: NLM
Share it on

Indian J Otolaryngol Head Neck Surg. 2000 Apr;52(2):151-8. doi: 10.1007/BF03000335.

Management of acute vertigo with betahistine.

Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India

R A Bradoo, N K Nerurkar, J B Mhapankar, S F Patil, D G Kute

Affiliations

  1. Senior Resident Department of ENT, L.T.M. Medical College & Hospital, Sion, 400022 Mumbai.

PMID: 23119656 PMCID: PMC3451274 DOI: 10.1007/BF03000335

Abstract

This open, prospective study was carried out in 29 outpatients of vertigo with Betahistine treatment at a dose of 16 mg three times daily far a maximum treatment period of 6 weeks or earlier until remission of vertigo attacks. The evaluations were carried out based on three parameters such as frequency, duration, and severity of vertigo attacks. Betahistino showed a significant improvement in the three parameters of frequency, duration and severity of vertigo attacks. Associated symptoms such as tinnitus, nausea, vomiting, headache, faintness showed a significant improvement with the therapy. Subgroup analysis showed a significant improvement of patients with severe and incapacitating verlign attaeks at baseline. Thus, this study proves excellent efficacy and goad tolerability of Betahistine as an anti-vertigo drug at a dose of 16 mg three times daily and gives a new insight for controlling acute or severe vertigo attacks without causing sedation.

References

  1. Laryngoscope. 1969 Nov;79(11):1956-79 - PubMed
  2. J Vestib Res. 1995 Jan-Feb;5(1):53-66 - PubMed
  3. Eur J Pharmacol. 1985 Apr 23;111(1):73-84 - PubMed
  4. J Laryngol Otol. 1981 Jul;95(7):687-92 - PubMed
  5. Arch Otorhinolaryngol. 1982;236(3):229-36 - PubMed
  6. Clin Otolaryngol Allied Sci. 1987 Apr;12(2):131-5 - PubMed
  7. Drugs. 1985 Sep;30(3):275-83 - PubMed
  8. Indian J Otolaryngol Head Neck Surg. 1999 Apr;51(2):27-36 - PubMed
  9. J Am Geriatr Soc. 1974 Sep;22(9):397-406 - PubMed

Publication Types